Xiamen-based global producer of natural vitamin E and other nutrition ingredients for food and supplement makers.
Xiamen-based global producer of natural vitamin E and other nutrition ingredients for food and supplement makers.
Extracts natural vitamin E from by-products of soybean-oil refining, so input costs follow edible-oil processing, and sells it by the tonne to supplement, food and feed makers. Its prices are shaped by competition from cheaper synthetic vitamin E, which a few large producers supply.
In one line: A Chinese DSM-Firmenich nutrition-ingredients unit.
Moat: narrow (scale, process know-how). One of the larger global natural vitamin E producers with integrated extraction know-how.
Headquarters: Xiamen, China · Employees: 2,184
Size Xiamen Kingdomway (002626.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.45B, the 1561st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.96 on 18 Nov 2026.
Performance Over six months the shares fell 3.3%, against -14.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 3.0% over the last twelve months (peer median +9.2%); the operating margin is 11.0% (peer median 9.4%).
Valuation It trades at 27.2× forward earnings against a peer median of 16.0× (3rd most expensive of 10).
Capital Return on invested capital runs 1.8 points above its cost of capital (5.9% WACC).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.40B | CN¥3.36B | CN¥3.24B | CN¥3.10B | CN¥3.00B |
| Revenue growth | — | +4% | +5% | +3% | — |
| Gross profit | CN¥1.44B | CN¥1.24B | CN¥1.16B | CN¥1.05B | CN¥1.11B |
| EBITDA | n/a | CN¥678M | CN¥662M | CN¥541M | CN¥616M |
| Net income | CN¥233M | CN¥340M | CN¥342M | CN¥277M | CN¥257M |
| Free cash flow | -CN¥402M | CN¥343M | CN¥165M | CN¥413M | CN¥536M |
| Capital expenditure | CN¥775M | CN¥230M | CN¥365M | CN¥252M | CN¥162M |
| Total debt | CN¥2.39B | CN¥2.53B | CN¥1.43B | CN¥916M | CN¥1.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Xiamen Kingdomway 002626.SZ | $1.45B | -3% | -3% | 11% | 27.2× | n/a |
| DSM-Firmenich DSFIR.AS | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% |
| Basf BAS.DE | $50.1B | 0% | -4% | 7% | 15.8× | 5.7% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002626.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.0% | -3.9% | 6th lowest of 21 |
| 6-month return | -3.3% | -14.9% | 6th highest of 21 |
| Distance from 52-week high | -25.8% | -41.0% | 6th highest of 21 |
| Revenue growth (TTM) | -3.0% | +9.2% | 8th lowest of 20 |
| Operating margin | 11.0% | 9.4% | 10th highest of 20 |
| Forward P/E | 27.2× | 16.0× | 3rd most expensive of 10 |
| ROIC minus cost of capital | +1.8 pp | -0.5 pp | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |